Leproust Emily M. sold $1.8M of TWST
Leproust Emily M. (Chief Executive Officer) sold 18,880 shares of Twist Bioscience Corp (TWST) at $95.00 ($1.79M total) on 2026-06-25 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The only new fact is the disclosed sale size, price, and 10b5-1 status; there are no accompanying fundamentals, guidance, or legal/operational updates.
Market read
Traders may briefly reassess sentiment around insider activity, but the 10b5-1 framing reduces the likelihood of a fundamental repricing catalyst.
What to watch
The article provides no context on total CEO holdings, prior sales cadence, or whether the sale size is typical; without that, the signal-to-noise is low.
Background
The article is an SEC Form 4 insider transaction disclosure for Twist Bioscience’s CEO.
Ticker impact
SEC Form 4 shows CEO Emily Leproust sold 18,880 shares at $95 on 2026-06-25 under a pre-arranged 10b5-1 plan.
Likely limited/short-lived impact; any reaction should fade unless accompanied by other disclosures.
The filing is a disclosed open-market sale with a stated 10b5-1 plan, and no new operating, financial, or regulatory facts are provided.
Market effects
No sector-level read-across; this is company-specific insider transaction data only.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, large CEO sales can still be interpreted by some traders as reduced confidence, especially if the stock is already under pressure.
Key entities
- issuerTwist Bioscience Corp
Subject of the Form 4 insider transaction disclosure.
- insiderEmily M. Leproust
CEO and director who sold shares under a pre-arranged 10b5-1 plan.
